Free Trial
NASDAQ:INBS

Intelligent Bio Solutions Q4 2025 Earnings Report

Intelligent Bio Solutions logo
$2.39 -0.01 (-0.42%)
As of 11:24 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Intelligent Bio Solutions EPS Results

Actual EPS
-$3.70
Consensus EPS
-$1.20
Beat/Miss
Missed by -$2.50
One Year Ago EPS
N/A

Intelligent Bio Solutions Revenue Results

Actual Revenue
$0.84 million
Expected Revenue
$4.30 million
Beat/Miss
Missed by -$3.46 million
YoY Revenue Growth
N/A

Intelligent Bio Solutions Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
Friday, August 15, 2025
Conference Call Time
8:00AM ET

Upcoming Earnings

Intelligent Bio Solutions' Q4 2026 earnings is estimated for Friday, August 14, 2026, based on past reporting schedules

Intelligent Bio Solutions Earnings Headlines

Ticker Revealed: Pre-IPO Access to "Next Elon Musk" Company
We’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.tc pixel
See More Intelligent Bio Solutions Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Intelligent Bio Solutions? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Intelligent Bio Solutions and other key companies, straight to your email.

About Intelligent Bio Solutions

Intelligent Bio Solutions (NASDAQ:INBS), Inc., through its wholly owned subsidiary, is focused on the design, development and marketing of rapid, real-time detection and identification systems for foodborne and environmental pathogens. The company’s flagship product, the RAPID-B System, integrates patented biosensor and fluorescence technologies to detect viable microorganisms in a fraction of the time required by traditional culture-based testing methods. This approach enables food processors, beverage producers, environmental testing laboratories and homeland security agencies to identify contaminants such as Escherichia coli O157:H7, Salmonella spp. and Listeria monocytogenes in under one hour.

In addition to the RAPID-B instrument, Intelligent Bio Solutions offers a portfolio of assay kits and consumables tailored for specific pathogen targets and sample matrices. These test kits have undergone evaluations by regulatory bodies including the U.S. Food and Drug Administration and the U.S. Department of Agriculture, and are used in quality control, process verification and regulatory compliance workflows. By shortening time-to-result and reducing labor and material costs, the company’s rapid testing solutions help organizations respond more quickly to contamination events and improve overall product safety.

Founded in 1998 and headquartered in Houston, Texas, Intelligent Bio Solutions serves a global customer base through direct sales and a network of distribution partners. The company’s leadership team combines expertise in biosensor engineering, microbiology and regulatory affairs to drive ongoing product innovation and market development. Looking ahead, Intelligent Bio Solutions seeks to expand its detection capabilities, broaden its application scope and enter new markets such as clinical diagnostics and pharmaceutical contamination monitoring.

View Intelligent Bio Solutions Profile